| Scrip Code | 531349 |
|---|---|
| NSE Symbol | PANACEABIO |
| MSEI Symbol | NOTLISTED |
| ISIN | INE922B01023 |
| Name of company | Panacea Biotec Limited |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2025 |
| Date of end of financial year | 31-03-2026 |
| Date of board meeting when results were approved | 30-05-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 26-05-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | Fourth quarter |
| Nature of report standalone or consolidated | Standalone |
| Whether results are audited or unaudited for the quarter ended | Audited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | Audited |
| Segment Reporting | Single segment |
| Description of single segment | Vaccines |
| Start date and time of board meeting | 30-05-2026 16:30:00 |
| End date and time of board meeting | 30-05-2026 20:10:00 |
| Whether cash flow statement is applicable on company | Yes |
| Type of cash flow statement | Cash Flow Indirect |
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Whether the company has any related party? | Yes |
| Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? | Yes |
| (I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public | No |
| (II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. | No |
| Whether the company is a high value debt listed entity according to regulation 15 (1A)? | No |
| (a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication? | |
| (b) If answer to above question is No, please explain the reason for not complying. | |
| Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? | Yes |
| Latest Date on which RPT policy is updated | 14-02-2025 |
| Indicate Company website link for updated RPT policy of the Company | https://media.panaceabiotec.com/policy/2025/policy-on-materiality-of-rpt-and-on-dealing-with-rpt.pdf |
| Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? | No |
| No. of times funds raised during the quarter | |
| Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? | No |
| There is no default. | |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-01-2026 | 01-04-2025 |
| B | Date of end of reporting period | 31-03-2026 | 31-03-2026 |
| C | Whether results are audited or unaudited | Audited | Audited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| 1 | Income | ||
| Revenue from operations | 11,112.00 | 41,349.00 | |
| Other income | 560.00 | 1,800.00 | |
| Total income | 11,672.00 | 43,149.00 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 5,879.00 | 21,949.00 |
| (b) | Purchases of stock-in-trade | 1.00 | 401.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | (299.00) | (1,242.00) |
| (d) | Employee benefit expense | 2,276.00 | 10,033.00 |
| (e) | Finance costs | 633.00 | 2,530.00 |
| (f) | Depreciation, depletion and amortisation expense | 418.00 | 1,875.00 |
| (f) | Other Expenses | ||
| 1 | Other Expenses | 3,225.00 | 11,988.00 |
| Total other expenses | 3,225.00 | 11,988.00 | |
| Total expenses | 12,133.00 | 47,534.00 | |
| 3 | Total profit before exceptional items and tax | (461.00) | (4,385.00) |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | (461.00) | (4,385.00) |
| 6 | Tax expense | ||
| 7 | Current tax | (159.00) | (159.00) |
| 8 | Deferred tax | (284.00) | (1,238.00) |
| 9 | Total tax expenses | (443.00) | (1,397.00) |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | (18.00) | (2,988.00) |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | (18.00) | (2,988.00) |
| 17 | Other comprehensive income net of taxes | 77.00 | 114.00 |
| 18 | Total Comprehensive Income for the period | 59.00 | (2,874.00) |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | |||
| Total profit or loss, attributable to non-controlling interests | |||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 613.00 | 613.00 | |
| Face value of equity share capital | 1 | 1 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | 27,911.00 | |
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | -0.03 | -4.88 | |
| Diluted earnings (loss) per share from continuing operations | -0.03 | 4.88 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | -0.03 | -4.88 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | -0.03 | 4.88 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | Notes: 1. The financial results for the quarter and year ended March 31, 2026 were reviewed by the Audit Committee at its meeting held on May 29, 2026 and approved by the Board of Directors of the Company at its meeting held on May 30, 2026, and have been audited by the statutory auditors of the Company. 2. The financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (“Ind AS”) notified under the Companies (Indian Accounting Standards) Rule, 2015, as amended from time to time, specified under section 133 of the Companies Act, 2013. 3. The consolidated financial results of the Company have been prepared by consolidating the Company's audited financial results of the Company and its material subsidiary for the respective periods, with the audited / unaudited (management reviewed and approved) financial results of other wholly owned subsidiaries (“WOS”) and the Enterprises over which the Company exercises control (the Company, these subsidiaries and the Enterprises hereinafter collectively referred to as “the Group”) are as follows: (i) Audited - Indian WOS: Panacea Biotec Pharma Limited (“PBPL”) & Meyten Realtech Private Limited; Overseas WOS: Panacea Biotec Inc. (WOS through PBPL); and Enterprises over which the Company exercises control*: PanEra Biotec Private Limited & Adveta Power Private Limited; and (ii) Unaudited - Overseas WOS: Panacea Biotec (International) S.A. (“PBS”) and Panacea Biotec Germany GmbH (WOS through PBS). *considered as a subsidiary for the purpose of consolidation as per Ind AS 110 4. For the financial year ended March 31, 2026, the Company and Group has incurred loss (including other comprehensive income) of Rs.2,874 Lakh and Rs.174 Lakh (year ended March 31, 2025: loss of Rs.1,518 Lakh and Rs.761 Lakh), respectively and as on March 31, 2026, the retained earnings of the Company are negative to the extent of Rs.21,782 Lakh (March 31, 2025: Rs.18,909 Lakh). The aforesaid conditions indicate the existence of uncertainty that may create doubt about the Company's ability to continue as a going concern. However, the retained earnings of the Group are positive to the extent of Rs.77,605 Lakh (March 31, 2025: Rs.77,991 Lakh). The surplus funds remaining with the Group out of the sales of pharmaceutical formulations brands in India and Nepal in March 2022 have helped in strengthening the working capital position, setting up new facilities for enhancement of capacities for manufacturing of vaccines drug substance, scaling up its nutrition and pharmaceutical formulations business and pursuing other business opportunities. The Company has already received higher long-term business orders for vaccines from key institutional customers. Based on these measures and continuous efforts to improve the business performance, the management has prepared the financial results on a going concern basis. |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | Year ended (dd-mm-yyyy) | ||
|---|---|---|---|
| Date of start of reporting period | 01-04-2025 | ||
| Date of end of reporting period | 31-03-2026 | ||
| Whether results are audited or unaudited | Audited | ||
| Nature of report standalone or consolidated | Standalone | ||
| Assets | |||
| 1 | Non-current assets | ||
| Property, plant and equipment | 34,739.00 | ||
| Capital work-in-progress | 9,135.00 | ||
| Investment property | 6,850.00 | ||
| Goodwill | 0.00 | ||
| Other intangible assets | 153.00 | ||
| Intangible assets under development | 3,998.00 | ||
| Biological assets other than bearer plants | 0.00 | ||
| Investments accounted for using equity method | 0.00 | ||
| Non-current financial assets | |||
| Non-current investments | 27.00 | ||
| Trade receivables, non-current | 0.00 | ||
| Loans, non-current | 0.00 | ||
| Other non-current financial assets | |||
| 1 | Other Financial Assets | 684.00 | |
| 2 | Income tax Assets | 1,175.00 | |
| 3 | Other non-current assets | 32.00 | |
| Total of other non-current financial assets | 1,891.00 | ||
| Total non-current financial assets | 1,918.00 | ||
| Deferred tax assets (net) | 0.00 | ||
| Other non-current assets | |||
| Total of other non-current assets | |||
| Total non-current assets | 56,793.00 | ||
| 2 | Current assets | ||
| Inventories | 12,634.00 | ||
| Current financial asset | |||
| Current investments | 0.00 | ||
| Trade receivables, current | 3,068.00 | ||
| Cash and cash equivalents | 241.00 | ||
| Bank balance other than cash and cash equivalents | 571.00 | ||
| Loans, current | 145.00 | ||
| Other current financial assets | |||
| Total of other current financial assets | 11,790.00 | ||
| Total current financial assets | 15,815.00 | ||
| Current tax assets (net) | |||
| Other current assets | |||
| Total of other current assets | |||
| Total current assets | 28,449.00 | ||
| 3 | Non-current assets classified as held for sale | ||
| 4 | Regulatory deferral account debit balances and related deferred tax Assets | ||
| Total assets | 85,242.00 | ||
| Equity and liabilities | |||
| 1 | Equity | ||
| Equity attributable to owners of parent | |||
| Equity share capital | 613.00 | ||
| Other equity | 27,911.00 | ||
| Total equity attributable to owners of parent | 28,524.00 | ||
| Non controlling interest | |||
| Total equity | 28,524.00 | ||
| 2 | Liabilities | ||
| Non-current liabilities | |||
| Non-current financial liabilities | |||
| Borrowings, non-current | 24,594.00 | ||
| Trade payables, non-current | |||
| (A) Total outstanding dues of micro enterprises and small enterprises | |||
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | |||
| Total Trade payable | |||
| Other non-current financial liabilities | |||
| 1 | Other financial liabilities | 1,392.00 | |
| Total of other non-current financial liabilities | 1,392.00 | ||
| Total non-current financial liabilities | 25,986.00 | ||
| Provisions, non-current | 2,014.00 | ||
| Deferred tax liabilities (net) | 199.00 | ||
| Deferred government grants, Non-current | |||
| Other non-current liabilities | |||
| Total of other non-current liabilities | |||
| Total non-current liabilities | 28,199.00 | ||
| Current liabilities | |||
| Current financial liabilities | |||
| Borrowings, current | 1,918.00 | ||
| Trade payables, current | |||
| (A) Total outstanding dues of micro enterprises and small enterprises | 1,453.00 | ||
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 11,891.00 | ||
| Total Trade payable | 13,344.00 | ||
| Other current financial liabilities | |||
| 1 | Current financial liabilities | 1,391.00 | |
| Total of other current financial liabilities | 1,391.00 | ||
| Total current financial liabilities | 16,653.00 | ||
| Other current liabilities | 8,643.00 | ||
| 1 | Other current liabilities | 8,643.00 | |
| Total of other current liabilities | 8,643.00 | ||
| Provisions, current | 3,223.00 | ||
| Current tax liabilities (Net) | |||
| Deferred government grants, Current | |||
| Total current liabilities | 28,519.00 | ||
| 3 | Liabilities directly associated with assets in disposal group classified as held for sale | ||
| 4 | Regulatory deferral account credit balances and related deferred tax liability | ||
| Total liabilities | 56,718.00 | ||
| Total equity and liabilites | 85,242.00 | ||
| Disclosure of notes on assets and liabilities | Textual Information(1) | ||
| Textual Information(1) | 5. During the financial year ended March 31, 2026, the Group has recognised exception income of Rs.1,950 Lakh (year ended March 31, 2025: Rs.3,599 Lakh) in the consolidated statement of profit and loss, which includes: (i) revenue of Rs.857 Lakh (year ended March 31, 2025: Nil), pursuant to the settlement agreement dated July 9, 2025 executed with Apotex Inc., USA (“Apotex”) to settle the ongoing dispute between Apotex and the Company & PBPL; and (ii) revenue of Rs.1,092 Lakh (year ended March 31, 2025: Rs.3,599 Lakh), out of the remaining deferred consideration of Rs.2,111 Lakh as at March 31, 2025, from sale of domestic pharmaceutical brands of PBPL. The balance deferred consideration of Rs.1,019 Lakh (March 31, 2025: Rs.2,111 Lakh) would be recognised in subsequent quarters / years and is shown as Contract Liability in the consolidated financial statements of the Group. 6. On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 (‘Labour Codes') which consolidate twenty-nine existing labour laws into a unified framework governing employee benefit during employment and post-employment. The Labour Codes, amongst other things, introduces changes including a uniform definition of wages. The incremental impact of these changes, assessed by the Company / Group, on the basis of the information available, consistent with the guidance provided by the Institute of Chartered Accountants of India, has been accounted for accordingly. Once Central / State Rules are notified by the Government on all the aspects of the Labour Codes, the Company / Group will evaluate additional impact, if any, on the measurement of employee benefits and would provide appropriate accounting effect. 7. The standalone and consolidated financial results for the year ended March 31, 2026 and March 31, 2025, include deferred tax (benefit) / charge of (Rs.153 Lakh) and Rs.36 Lakh {March 31, 2025: (Rs.416 Lakh) and Rs.270 Lakh}, respectively on account of adjustments pertaining to earlier years. 8. During the quarter ended March 31, 2026, the enrollment of study participants in context of DengiAll� Phase-III clinical trial has been completed. DengiAll� will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027 after successful completion of the clinical trial and receipt of necessary regulatory approvals. 9. Amounts for the quarter ended March 31, 2026 and March 31, 2025 represent the balancing amounts between the audited amounts for the full financial year and the published year to date amounts upto third quarter of the respective financial years, which had been subjected only to limited review. 10. The Company publishes standalone financial results along with the consolidated financial results. In accordance with Ind AS 108, ‘Operating Segments’, the management has disclosed the segment information in the consolidated financial results. Accordingly, the segment information is given in the consolidated financial results of the Group for the quarter and year ended March 31, 2026. 11. The necessary certificate / report in respect of the above results in terms of requirements of Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015, has been placed before the Board of Directors. 12. Previous period amounts have been regrouped/ reclassified in compliance with Ind-AS to make them comparable with those of current period / year. 13. ‘0’ under “Rs. in Lakh” represents an amount less than Rs.50,000. Further, the figures shown in the tables may not exactly add up due to rounding off. 14. The above results are also available on the Company’s website https://www.panaceabiotec.com |
|---|
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-01-2026 | 01-04-2025 | |||||
| Date of end of reporting period | 31-03-2026 | 31-03-2026 | |||||
| Whether results are audited or unaudited | Audited | Audited | |||||
| Nature of report standalone or consolidated | Standalone | Standalone | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-01-2026 | 01-04-2025 |
| B | Date of end of reporting period | 31-03-2026 | 31-03-2026 |
| C | Whether results are audited or unaudited | Audited | Audited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Items that will not be reclassified to profit or loss | 104.00 | 153.00 |
| Total Amount of items that will not be reclassified to profit and loss | 104.00 | 153.00 | |
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 27.00 | 39.00 |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0.00 | 0.00 |
| 5 | Total Other comprehensive income | 77.00 | 114.00 |
| Particulars | Year ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|
| A | Date of start of reporting period | 01-04-2025 | ||||
| B | Date of end of reporting period | 31-03-2026 | ||||
| C | Whether results are audited or unaudited | Audited | ||||
| D | Nature of report standalone or consolidated | Standalone | ||||
| Statement of cash flows | ||||||
| Cash flows from used in operating activities | ||||||
| Profit before tax | (4,385.00) | |||||
| Adjustments for reconcile profit (loss) | ||||||
| Adjustments for finance costs | 2,530.00 | |||||
| Adjustments for decrease (increase) in inventories | 2,576.00 | |||||
| Adjustments for decrease (increase) in trade receivables, current | (1,002.00) | |||||
| Adjustments for decrease (increase) in trade receivables, non-current | 0.00 | |||||
| Adjustments for decrease (increase) in other current assets | 621.00 | |||||
| Adjustments for decrease (increase) in other non-current assets | 41.00 | |||||
| Adjustments for other financial assets, non-current | (43.00) | |||||
| Adjustments for other financial assets, current | (2,866.00) | |||||
| Adjustments for other bank balances | 0.00 | |||||
| Adjustments for increase (decrease) in trade payables, current | (3,753.00) | |||||
| Adjustments for increase (decrease) in trade payables, non-current | 0.00 | |||||
| Adjustments for increase (decrease) in other current liabilities | 796.00 | |||||
| Adjustments for increase (decrease) in other non-current liabilities | 0.00 | |||||
| Adjustments for depreciation and amortisation expense | 1,875.00 | |||||
| Adjustments for impairment loss reversal of impairment loss recognised in profit or loss | 0.00 | |||||
| Adjustments for provisions, current | 131.00 | |||||
| Adjustments for provisions, non-current | 172.00 | |||||
| Adjustments for other financial liabilities, current | (73.00) | |||||
| Adjustments for other financial liabilities, non-current | 0.00 | |||||
| Adjustments for unrealised foreign exchange losses gains | 642.00 | |||||
| Adjustments for dividend income | 0.00 | |||||
| Adjustments for interest income | 1,119.00 | |||||
| Adjustments for share-based payments | 0.00 | |||||
| Adjustments for fair value losses (gains) | 0.00 | |||||
| Adjustments for undistributed profits of associates | 0.00 | |||||
| Other adjustments for which cash effects are investing or financing cash flow | 0.00 | |||||
| Other adjustments to reconcile profit (loss) | 0.00 | |||||
| Other adjustments for non-cash items | 759.00 | |||||
| Share of profit and loss from partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Total adjustments for reconcile profit (loss) | 1,287.00 | |||||
| Net cash flows from (used in) operations | (3,098.00) | |||||
| Dividends received | 0.00 | |||||
| Interest paid | 0.00 | |||||
| Interest received | 0.00 | |||||
| Income taxes paid (refund) | 431.00 | |||||
| Other inflows (outflows) of cash | (486.00) | |||||
| Net cash flows from (used in) operating activities | (4,015.00) | |||||
| Cash flows from used in investing activities | ||||||
| Cash flows from losing control of subsidiaries or other businesses | 0.00 | |||||
| Cash flows used in obtaining control of subsidiaries or other businesses | 0.00 | |||||
| Other cash receipts from sales of equity or debt instruments of other entities | 0.00 | |||||
| Other cash payments to acquire equity or debt instruments of other entities | 0.00 | |||||
| Other cash receipts from sales of interests in joint ventures | 0.00 | |||||
| Other cash payments to acquire interests in joint ventures | 0.00 | |||||
| Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Cash payment for investment in partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Proceeds from sales of property, plant and equipment | 0.00 | |||||
| Purchase of property, plant and equipment | 3,373.00 | |||||
| Proceeds from sales of investment property | 0.00 | |||||
| Purchase of investment property | 0.00 | |||||
| Proceeds from sales of intangible assets | 0.00 | |||||
| Purchase of intangible assets | 0.00 | |||||
| Proceeds from sales of intangible assets under development | 0.00 | |||||
| Purchase of intangible assets under development | 0.00 | |||||
| Proceeds from sales of goodwill | 0.00 | |||||
| Purchase of goodwill | 0.00 | |||||
| Proceeds from biological assets other than bearer plants | 0.00 | |||||
| Purchase of biological assets other than bearer plants | 0.00 | |||||
| Proceeds from government grants | 0.00 | |||||
| Proceeds from sales of other long-term assets | 0.00 | |||||
| Purchase of other long-term assets | 0.00 | |||||
| Cash advances and loans made to other parties | 0.00 | |||||
| Cash receipts from repayment of advances and loans made to other parties | 0.00 | |||||
| Cash payments for future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Cash receipts from future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Dividends received | 0.00 | |||||
| Interest received | 349.00 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | 1,171.00 | |||||
| Net cash flows from (used in) investing activities | (1,853.00) | |||||
| Cash flows from used in financing activities | ||||||
| Proceeds from changes in ownership interests in subsidiaries | 0.00 | |||||
| Payments from changes in ownership interests in subsidiaries | 0.00 | |||||
| Proceeds from issuing shares | 0.00 | |||||
| Proceeds from issuing other equity instruments | 0.00 | |||||
| Payments to acquire or redeem entity's shares | 0.00 | |||||
| Payments of other equity instruments | 0.00 | |||||
| Proceeds from exercise of stock options | 0.00 | |||||
| Proceeds from issuing debentures notes bonds etc | 0.00 | |||||
| Proceeds from borrowings | 21,038.00 | |||||
| Repayments of borrowings | 18,275.00 | |||||
| Payments of lease liabilities | 0.00 | |||||
| Dividends paid | 0.00 | |||||
| Interest paid | 509.00 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) financing activities | 2,254.00 | |||||
| Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes | (3,614.00) | |||||
| Effect of exchange rate changes on cash and cash equivalents | ||||||
| Effect of exchange rate changes on cash and cash equivalents | 5.00 | |||||
| Net increase (decrease) in cash and cash equivalents | (3,609.00) | |||||
| Cash and cash equivalents cash flow statement at beginning of period | 3,850.00 | |||||
| Cash and cash equivalents cash flow statement at end of period | 241.00 | |||||
| Whether results are audited or unaudited | Audited |
|---|---|
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Auditor's opinion | |
| Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results | Yes |
| Sr No. | Audit firm's name | Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI | Certificate valid upto | ||
| 1 | M/s Suresh Surana & Associates LLP | Yes | 31-03-2028 | ||
|---|---|---|---|---|---|
Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter) |
| Sr No. | Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. | ||||||||||||||||||||||||
| Details of the party (listed entity/subsidiary) entering into the transaction | Details of the counterparty | Type of related party transaction | Details of other related party transaction | Value of the related party transaction as approved by the audit committee | Remarks on approval by audit committee | Value of the related party transaction ratified by the audit committee | Date of Audit Committee Meeting where the ratification was approved | Value of transaction during the reporting period | In case monies are due to either party as a result of the transaction | In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments | Details of the loans, inter-corporate deposits, advances or investments | Notes | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | PAN | Name | PAN | Relationship of the counterparty with the listed entity or its subsidiary | Opening balance | Closing balance | Nature of indebtedness (loan/ issuance of debt/ any other etc.) | Details of other indebtedness | Cost | Tenure | Nature (loan/ advance/ intercorporate deposit/ investment ) | Interest Rate (%) | Tenure | Secured/ unsecured | Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage) | ||||||||||
| 1 | Panacea Biotec Limited | Adveta Power Private Limited | Joint Venture | Any other transaction | Rental Income | As approved by Board | 0.51 | 7.30 | 7.91 | ||||||||||||||||
| 2 | Panacea Biotec Limited | Adveta Power Private Limited | Joint Venture | Investment | As approved by Board | 0.00 | 9.00 | 9.00 | |||||||||||||||||
| 3 | Panacea Biotec Pharma Limited | Adveta Power Private Limited | Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence | Any other transaction | Interest accrued on loans given | As approved by Board | 0.24 | 0.24 | 0.48 | ||||||||||||||||
| 4 | Panacea Biotec Pharma Limited | Adveta Power Private Limited | Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence | Loan | As approved by Board | 0.00 | 5.90 | 5.90 | |||||||||||||||||
| 5 | Panacea Biotec Pharma Limited | Adveta Power Private Limited | Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence | Interest received | As approved by Board | 0.26 | 0.24 | 0.48 | |||||||||||||||||
| 6 | Panacea Biotec Pharma Limited | Adveta Power Private Limited | Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence | Any other transaction | Allowance for interest accrued on loan | As approved by Board | 0.26 | 0.00 | 0.48 | ||||||||||||||||
| 7 | Panacea Biotec Pharma Limited | Adveta Power Private Limited | Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence | Any other transaction | Provision made on loan given | As approved by Board | 5.90 | 0.00 | 0.00 | ||||||||||||||||
| 8 | Panacea Biotec Limited | CA Rajesh Jain | Independent Director | Remuneration | As approved by Nomination and Remuneration Committee and Board | 5.50 | 0.00 | 0.00 | |||||||||||||||||
| 9 | Panacea Biotec Pharma Limited | CA Rajesh Jain | Independent Director | Remuneration | As approved by Board | 3.50 | 0.00 | 0.00 | |||||||||||||||||
| 10 | Panacea Biotec Limited | Dr. Rajender Pal Singh | Independent Director | Remuneration | As approved by Nomination and Remuneration Committee and Board | 3.25 | 0.00 | 0.00 | |||||||||||||||||
| 11 | Panacea Biotec Limited | Dr. Rajesh Jain | Chairman and Managing Director | Interest paid | As approved by Board | 39.18 | 61.53 | 16.46 | |||||||||||||||||
| 12 | Panacea Biotec Limited | Dr. Rajesh Jain | Chairman and Managing Director | Loan | As approved by Board | 0.00 | 1,500.00 | 1,500.00 | |||||||||||||||||
| 13 | Panacea Biotec Limited | Dr. Rajesh Jain | Chairman and Managing Director | Remuneration | As approved by Nomination and Remuneration Committee, Board and Shareholders | 42.46 | 0.00 | 0.00 | |||||||||||||||||
| 14 | Panacea Biotec Pharma Limited | Dr. Sanjay Trehan | Whole-time Director | Purchase of goods or services | As approved by Board | 11.43 | 0.74 | 3.27 | |||||||||||||||||
| 15 | Panacea Biotec Pharma Limited | Dr. Sanjay Trehan | Whole-time Director | Remuneration | As approved by Board and Shareholders | 4.20 | 0.00 | 0.00 | |||||||||||||||||
| 16 | Panacea Biotec Limited | Dr. Sanjay Trehan | Whole-time Director | Remuneration | As approved by Nomination and Remuneration Committee, Board and Shareholders | 4.20 | 0.00 | 0.00 | |||||||||||||||||
| 17 | Panacea Biotec Limited | Dr. Sanjay Trehan | Whole-time Director | Purchase of goods or services | As approved by Board | 9.45 | 0.00 | 0.00 | |||||||||||||||||
| 18 | Panacea Biotec Limited | Dr. Venkatesh Sarvasiddhi | Independent Director | Remuneration | As approved by Nomination and Remuneration Committee and Board | 3.25 | 0.00 | 0.00 | |||||||||||||||||
| 19 | Panacea Biotec Limited | Meyten Realtech Private Limited | Wholly owned subsidiary | Any other transaction | Rental Income | As approved by Board | 0.01 | 0.25 | 0.23 | ||||||||||||||||
| 20 | Panacea Biotec Limited | Meyten Realtech Private Limited | Wholly owned subsidiary | Any other transaction | Rent paid | As approved by Board | 5.96 | 10.62 | 5.00 | ||||||||||||||||
| 21 | Panacea Biotec Limited | Meyten Realtech Private Limited | Wholly owned subsidiary | Investment | As approved by Board | 0.00 | 1.00 | 1.00 | |||||||||||||||||
| 22 | Panacea Biotec Limited | MR Lex Corp LLP | Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence | Purchase of goods or services | As approved by Board | 7.79 | 3.10 | 6.04 | |||||||||||||||||
| 23 | Panacea Biotec Pharma Limited | MR Lex Corp LLP | Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence | Purchase of goods or services | As approved by Board | 4.98 | 0.74 | 3.83 | |||||||||||||||||
| 24 | Panacea Biotec Limited | Mr. Ankesh Jain | Whole - time Director | Remuneration | As approved by Board | 2.00 | 0.00 | 0.00 | |||||||||||||||||
| 25 | Panacea Biotec Pharma Limited | Mr. Ankesh Jain | Whole - time Director | Any other transaction | Post Emploment Benefits | As approved by Board | 0.00 | 0.00 | 15.75 | ||||||||||||||||
| 26 | Panacea Biotec Pharma Limited | Mr. Ankesh Jain | Whole-time Director | Remuneration | As approved by Board | 22.70 | 0.00 | 0.00 | |||||||||||||||||
| 27 | Panacea Biotec Limited | Mr. Ankit Jain | General Manager - Legal & Company Secretary (w.e.f. December 16, 2025) | Remuneration | As approved Nomination and Remuneration Committee and Board | 13.95 | 0.00 | 0.00 | |||||||||||||||||
| 28 | Panacea Biotec Limited | Mr. Ankit Jain | General Manager - Legal & Company Secretary (w.e.f. December 16, 2025) | Any other transaction | Post Emploment Benefits | As approved Nomination and Remuneration Committee and Board | 0.00 | 0.00 | 1.25 | ||||||||||||||||
| 29 | Panacea Biotec Limited | Mr. Ashwani Jain | Chief Operating Officer | Remuneration | As approved by Board | 15.10 | 0.00 | 0.00 | |||||||||||||||||
| 30 | Panacea Biotec Limited | Mr. Ashwani Jain | Chief Operating Officer | Any other transaction | Post Emploment Benefits | As approved by Board | 0.00 | 0.00 | 20.00 | ||||||||||||||||
| 31 | Panacea Biotec Limited | Mr. Devender Gupta | CFO and Head Information Technology (Till December 15, 2025) | Remuneration | As approved by Nomination and Remuneration Committee and Board | 40.72 | 0.00 | 0.00 | |||||||||||||||||
| 32 | Panacea Biotec Limited | Mr. Harshet Jain | Whole-time Director | Remuneration | As approved by Nomination and Remuneration Committee, Board and Shareholders | 18.20 | 0.00 | 0.00 | |||||||||||||||||
| 33 | Panacea Biotec Limited | Mr. Harshet Jain | Whole-time Director | Any other transaction | Post Emploment Benefits | As approved by Nomination and Remuneration Committee, Board and Shareholders | 0.00 | 0.00 | 5.68 | ||||||||||||||||
| 34 | Panacea Biotec Limited | Mr. Krishan Kumar Jalan | Independent Director | Remuneration | As approved by Nomination and Remuneration Committee and Board | 3.25 | 0.00 | 0.00 | |||||||||||||||||
| 35 | Panacea Biotec Limited | Mr. Mukul Gupta | Independent Director | Remuneration | As approved by Nomination and Remuneration Committee and Board | 6.00 | 0.00 | 0.00 | |||||||||||||||||
| 36 | Panacea Biotec Limited | Mr. Rajesh Jain | Independent Director | Any other transaction | Post Emploment Benefits | As approved by Nomination and Remuneration Committee and Board | 0.00 | 0.00 | 196.85 | ||||||||||||||||
| 37 | Panacea Biotec Limited | Mr. Sandeep Jain | Joint Managing Director | Remuneration | As approved by Nomination and Remuneration Committee, Board and Shareholders | 40.33 | 0.00 | 0.00 | |||||||||||||||||
| 38 | Panacea Biotec Limited | Mr. Sandeep Jain | Joint Managing Director | Any other transaction | Post Emploment Benefits | As approved by Nomination and Remuneration Committee, Board and Shareholders | 0.00 | 0.00 | 191.30 | ||||||||||||||||
| 39 | Panacea Biotec Limited | Mr. Tanish Jain | Manager Global Sourcing (Biologicals) | Remuneration | As approved by Board | 8.44 | 0.00 | 0.00 | |||||||||||||||||
| 40 | Panacea Biotec Limited | Mr. Tanish Jain | Manager Global Sourcing (Biologicals) | Any other transaction | Post Emploment Benefits | As approved by Board | 0.00 | 0.00 | 1.18 | ||||||||||||||||
| 41 | Panacea Biotec Pharma Limited | Mr. Taric Jain | Sr. Software Engineer | Remuneration | As approved by Board | 14.14 | 0.00 | 0.00 | |||||||||||||||||
| 42 | Panacea Biotec Pharma Limited | Mr. Taric Jain | Sr. Software Engineer | Any other transaction | Post Emploment Benefits | As approved by Board | 0.00 | 0.00 | 1.81 | ||||||||||||||||
| 43 | Panacea Biotec Limited | Mr. Vinod Goel | Group CFO and Head Legal & Corporate Governance | Remuneration | As approved by Nomination and Remuneration Committee and Board | 44.18 | 0.00 | 0.00 | |||||||||||||||||
| 44 | Panacea Biotec Limited | Mr. Vinod Goel | Group CFO and Head Legal & Corporate Governance | Any other transaction | Post Emploment Benefits | As approved by Nomination and Remuneration Committee and Board | 0.00 | 0.00 | 20.00 | ||||||||||||||||
| 45 | Panacea Biotec Limited | Mrs. Ambika Sharma | Independent Director | Remuneration | As approved by Board | 5.50 | 0.00 | 0.00 | |||||||||||||||||
| 46 | Panacea Biotec Pharma Limited | Mrs. Manjula Upadhyay | Independent Director | Remuneration | As approved by Board | 3.00 | 0.00 | 0.00 | |||||||||||||||||
| 47 | Panacea Biotec Limited | Neophar Alipro Limited | Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence | Any other transaction | Rental Income | As approved by Board | 0.90 | 0.00 | 0.00 | ||||||||||||||||
| 48 | Panacea Biotec Limited | Panacea Biotec (International) S.A., Switzerland | Wholly owned subsidiary | Any other transaction | Allowance for doubtful loan | As approved by Board | 0.00 | 1,390.04 | 1,390.04 | ||||||||||||||||
| 49 | Panacea Biotec Limited | Panacea Biotec (International) S.A., Switzerland | Wholly owned subsidiary | Loan | As approved by Board | 0.00 | 1,390.04 | 1,390.04 | |||||||||||||||||
| 50 | Panacea Biotec Limited | Panacea Biotec (International) S.A., Switzerland | Wholly owned subsidiary | Investment | As approved by Board | 0.00 | 343.61 | 343.61 | |||||||||||||||||
| 51 | Panacea Biotec Limited | Panacea Biotec (International) S.A., Switzerland | Wholly owned subsidiary | Any other transaction | Provision for impairment of Investment | As approved by Board | 0.00 | 343.61 | 343.61 | ||||||||||||||||
| 52 | Panacea Biotec Limited | Panacea Biotec (International) S.A., Switzerland | Wholly owned subsidiary | Interest received | As approved by Board | 91.69 | 0.00 | 0.00 | |||||||||||||||||
| 53 | Panacea Biotec Limited | Panacea Biotec (International) S.A., Switzerland | Wholly owned subsidiary | Any other transaction | Provision for impairment of Interest Income | As approved by Board | 91.69 | 242.74 | 179.23 | ||||||||||||||||
| 54 | Panacea Biotec Limited | Panacea Biotec (International) S.A., Switzerland | Wholly owned subsidiary | Any other transaction | Provision of interest on Loan | As approved by Board | 91.69 | 0.00 | 179.23 | ||||||||||||||||
| 55 | Panacea Biotec Limited | Panacea Biotec (International) S.A., Switzerland | Wholly owned subsidiary | Any other transaction | Allowance for interest accrued on Loan | As approved by Board | 91.69 | 0.00 | 179.23 | ||||||||||||||||
| 56 | Panacea Biotec Pharma Limited | Panacea Biotec Germany Gmbh | Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence | Sale of goods or services | As approved by Board | 5.60 | 0.00 | 0.00 | |||||||||||||||||
| 57 | Panacea Biotec Limited | Panacea Biotec Germany Gmbh | Indirect Subsidiary | Any other transaction | Allowance for doubtful loan | As approved by Board | 0.00 | 4,589.01 | 4,589.01 | ||||||||||||||||
| 58 | Panacea Biotec Limited | Panacea Biotec Germany Gmbh | Indirect Subsidiary | Loan | As approved by Board | 0.00 | 4,589.01 | 4,589.01 | |||||||||||||||||
| 59 | Panacea Biotec Limited | Panacea Biotec Germany Gmbh | Indirect Subsidiary | Interest received | As approved by Board | 302.66 | 0.00 | 0.00 | |||||||||||||||||
| 60 | Panacea Biotec Limited | Panacea Biotec Germany Gmbh | Indirect Subsidiary | Any other transaction | Provision for impairment of Interest Income | As approved by Board | 302.66 | 801.31 | 1,103.97 | ||||||||||||||||
| 61 | Panacea Biotec Limited | Panacea Biotec Germany Gmbh | Indirect Subsidiary | Any other transaction | Trade Receivable | As approved by Board | 0.00 | 13.04 | 13.48 | ||||||||||||||||
| 62 | Panacea Biotec Limited | Panacea Biotec Germany Gmbh | Indirect Subsidiary | Any other transaction | Trade Payable | As approved by Board | 0.00 | 245.94 | 254.18 | ||||||||||||||||
| 63 | Panacea Biotec Pharma Limited | Panacea Biotec Germany Gmbh | Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence | Any other transaction | Trade Receivable | As approved by Board | 0.00 | 126.35 | 5.82 | ||||||||||||||||
| 64 | Panacea Biotec Pharma Limited | Panacea Biotec Germany Gmbh | Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence | Any other transaction | Trade Payable | As approved by Board | 0.00 | 96.70 | 99.94 | ||||||||||||||||
| 65 | Panacea Biotec Limited | Panacea Biotec Germany Gmbh | Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence | Any other transaction | Provision of interest on Loan | As approved by Board | 302.66 | 0.00 | 591.65 | ||||||||||||||||
| 66 | Panacea Biotec Limited | Panacea Biotec Germany Gmbh | Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence | Any other transaction | Allowance for interest accrued on Loan | As approved by Board | 302.66 | 0.00 | 591.65 | ||||||||||||||||
| 67 | Panacea Biotec Pharma Limited | Panacea Biotec Inc. | Wholly owned subsidiary | Investment | As approved by Board | 0.00 | 854.92 | 854.92 | |||||||||||||||||
| 68 | Panacea Biotec Pharma Limited | Panacea Biotec Inc. | Wholly owned subsidiary | Sale of goods or services | As approved by Board | 17.34 | 0.00 | 18.75 | |||||||||||||||||
| 69 | Panacea Biotec Pharma Limited | Panacea Biotec Inc. | Wholly owned subsidiary | Any other transaction | Provisions for impairment of investment | As approved by Board | 398.28 | 0.00 | 398.28 | ||||||||||||||||
| 70 | Panacea Biotec Limited | Panacea Biotec Inc. | Indirect Subsidiary | Any other transaction | Provision for interest on loan | As approved by Board | 91.69 | 0.00 | 91.69 | ||||||||||||||||
| 71 | Panacea Biotec Limited | Panacea Biotec Pharma Limited | Wholly owned subsidiary | Any other transaction | Trade Payable | As approved by Board | 0.00 | 207.46 | 908.21 | ||||||||||||||||
| 72 | Panacea Biotec Limited | Panacea Biotec Pharma Limited | Wholly owned subsidiary | Any other transaction | Rental Income | As approved by Board | 136.70 | 0.00 | 406.17 | ||||||||||||||||
| 73 | Panacea Biotec Limited | Panacea Biotec Pharma Limited | Wholly owned subsidiary | Any other transaction | Interest Expense and Interest accrued on borrowing | As approved by Board | 1,097.72 | 930.86 | 1,920.03 | ||||||||||||||||
| 74 | Panacea Biotec Limited | Panacea Biotec Pharma Limited | Wholly owned subsidiary | Purchase of goods or services | As approved by Board | 204.52 | 0.00 | 0.00 | |||||||||||||||||
| 75 | Panacea Biotec Limited | Panacea Biotec Pharma Limited | Wholly owned subsidiary | Any other transaction | Reimbursement of expenses | As approved by Board | 128.91 | 0.00 | 0.00 | ||||||||||||||||
| 76 | Panacea Biotec Limited | Panacea Biotec Pharma Limited | Wholly owned subsidiary | Any other transaction | Recovery of expenses | As approved by Board | 39.23 | 0.00 | 0.00 | ||||||||||||||||
| 77 | Panacea Biotec Limited | Panacea Biotec Pharma Limited | Wholly owned subsidiary | Investment | As approved by Board | 0.00 | 10.00 | 10.00 | |||||||||||||||||
| 78 | Panacea Biotec Limited | Panacea Biotec Pharma Limited | Wholly owned subsidiary | Any other transaction | Borrowings | As approved by Board | 1,568.63 | 25,713.92 | 24,145.29 | ||||||||||||||||
| 79 | Panacea Biotec Limited | Panacea Biotec Pharma Limited | Wholly owned subsidiary | Any other transaction | Rent paid | As approved by Board | 0.57 | 0.00 | 0.00 | ||||||||||||||||
| 80 | Panacea Biotec Limited | Panacea Biotec Pharma Limited | Wholly owned subsidiary | Sale of goods or services | As approved by Board | 323.61 | 0.00 | 0.00 | |||||||||||||||||
| 81 | Panacea Biotec Limited | PanEra Biotec Private Limited | Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence | Any other transaction | Rental Income | As approved by Board | 0.81 | 5.09 | 6.01 | ||||||||||||||||
| 82 | Panacea Biotec Limited | PanEra Biotec Private Limited | Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence | Investment | As approved by Board | 0.00 | 41.98 | 41.98 | |||||||||||||||||
| 83 | Panacea Biotec Limited | PanEra Biotec Private Limited | Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence | Any other transaction | Provision for impairment of Investment | As approved by Board | 0.00 | 41.98 | 41.98 | ||||||||||||||||
| 84 | Panacea Biotec Pharma Limited | PanEra Biotec Private Limited | Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence | Any other transaction | Interest income and Interest Accrued | As approved by Board | 34.41 | 30.98 | 61.95 | ||||||||||||||||
| 85 | Panacea Biotec Pharma Limited | PanEra Biotec Private Limited | Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence | Any other transaction | Provision made on Interest earned/accrued | As approved by Board | 34.41 | 30.98 | 61.95 | ||||||||||||||||
| 86 | Panacea Biotec Pharma Limited | PanEra Biotec Private Limited | Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence | Loan | As approved by Board | 3.00 | 764.49 | 767.49 | |||||||||||||||||
| 87 | Panacea Biotec Pharma Limited | PanEra Biotec Private Limited | Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence | Any other transaction | Provision made on loan given | As approved by Board | 3.00 | 764.49 | 767.49 | ||||||||||||||||
| 88 | Panacea Biotec Limited | Rees Investment Limited | Wholly owned subsidiary (Liquidated on May 23, 2019) | Loan | As approved by Board | 0.00 | 5,851.59 | 5,851.59 | |||||||||||||||||
| 89 | Panacea Biotec Limited | Rees Investment Limited | Wholly owned subsidiary (Liquidated on May 23, 2019) | Any other transaction | Provision made on loan given | As approved by Board | 0.00 | 5,851.59 | 5,851.59 | ||||||||||||||||
| Total value of transaction during the reporting period | 6,056.57 | ||||||||||||||||||||||||